Medipharm eyes U.S. cannabis rescheduling status

Executive Summary

• Medipharm Labs highlights its strategic positioning regarding the potential federal rescheduling of cannabis in the United States from Schedule I to Schedule III.
• The company emphasizes its existing regulatory infrastructure, including a completed FDA site registration for its manufacturing facility and a filed Drug Master File (DMF) for its CBD active pharmaceutical ingredient (API).
• Medipharm asserts it is uniquely positioned among North American public cannabis companies to support expanded U.S.-based medical research and special access programs due to its FDA-inspected facility and DEA import permits.

Key Details

• Regulatory Context: The U.S. administration is reviewing the rescheduling of cannabis, potentially moving it from Schedule I to Schedule III, which would recognize medical benefits and reduce restrictions on financing and undertaking research.
• FDA Site Registration: Medipharm completed a complex foreign drug manufacturing site registration with the U.S. FDA, including a week-long inspection, granting the company the ability to produce, label, test, and release drugs.
• Drug Master File (DMF): The company has filed a DMF with the U.S. FDA for its CBD API, a critical requirement for sourcing CBD for late-stage clinical trials and finished dose products.
• Operational History: Medipharm has already shipped medical cannabis API and products to the U.S. for research, including a National Institutes of Health (NIH)-financed clinical trial, utilizing FDA site registration and DEA import permits.
• Competitive Advantage: The company claims no other publicly listed cannabis-focused company in North America holds this specific stack of licensing, including an FDA-inspected cannabis facility, which typically takes years to achieve.
• Strategic Goal: Medipharm aims to serve the anticipated expansion of U.S.-based research and new medical special access programs upon rescheduling.

Notable Quotes

• "To Medipharm's understanding no other publicly listed cannabis-focused company in North America has this stack of licensing, including an FDA-inspected cannabis facility. It takes years of regulatory and quality activities to achieve this suite of licensing and enable clinical research with pharmaceutical cannabis."